Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma

Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Blood (Impact Factor: 10.43). 04/2007; 109(8):3409-16. DOI: 10.1182/blood-2006-09-047621
Source: PubMed

ABSTRACT Standard chemotherapy fails in 40% to 50% of patients with diffuse large B-cell lymphoma (DLBCL). Some of these failures can be salvaged with high-dose regimens, suggesting a role for drug resistance in this disease. We examined the expression of genes in the glutathione (GSH) and ATP-dependent transporter (ABC) families in 2 independent tissue-based expression microarray datasets obtained prior to therapy from patients with DLBCL. Among genes in the GSH family, glutathione peroxidase 1 (GPX1) had the most significant adverse effect on disease-specific overall survival (dOS) in the primary dataset (n = 130) (HR: 1.68; 95% CI: 1.26-2.22; P < .001). This effect remained statistically significant after controlling for biologic signature, LLMPP cell-of-origin signature, and IPI score, and was confirmed in the validation dataset (n = 39) (HR: 1.7; 95% CI: 1.05-2.8; P = .033). Recursive partitioning identified a group of patients with low-level expression of GPX1 and multidrug resistance 1 (MDR1; ABCB1) without early treatment failures and with superior dOS (P < .001). Overall, our findings suggest an important association of oxidative-stress defense and drug elimination with treatment failure in DLBCL and identify GPX1 and ABCB1 as potentially powerful biomarkers of early failure and disease-specific survival.

Download full-text


Available from: Rachel S Rogers (Hammond), Sep 17, 2014
  • Source
    • "One of the most interesting previous observations, concerns the significant correlation between the concentration of antioxidant enzymes, inflammatory proteins and the clinical status of the patient, such as to attribute a prognostic role to oxidative stress parameters (Mantovani et al. 2002).The prognostic role of oxidative stress in human lymphomas has also been studied, with conflicting results. According to some authors , the worst prognosis were those with decreased expression of antioxidant enzymes, but, according to others, the conclusions were exactly the opposite (Tome et al. 2005; Andreadis et al. 2007; Peroja et al. 2012). Even the use of chemotherapeutics can significantly affect the production of radical species and therefore, the consumption of antioxidants. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the last 20 years, an increasing interest toward oxidative stress has been documented in order to investigate their direct or indirect involvement in several mechanisms regarding oncogenesis and lymphomas in particular. The aim of this paper was to evaluate oxidative stress in dogs affected by malignant lymphoma in comparison to a control group, to investigate what factors can affect this status, and to point out similarities and differences with human. Forty-eight samples from four subjects, affected by high-grade centroblastic polymorphic lymphoma and receiving a standard chemotherapy, have been processed for derivatives of reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) tests. The obtained data show a condition of oxidative stress in dogs with lymphoma, with a significant increase in reactive oxygen species (ROS) plasma levels and a decrease in antioxidant capacity. No significant differences emerged on the basis of remission. Further results of canine studies about oxidative status in lymphomas could be a model for human, according to analogy between them.
    Comparative Clinical Pathology 01/2013; 24(1). DOI:10.1007/s00580-013-1856-8
  • Source
    • "We previously reported that DLBCL patients with high ABCG2 protein expression showed significantly shorter overall survival and failure free-survival compared with patients with tumors with low or no expression of ABCG2 (Kim et al., 2009). However, Andreadis and colleagues (Andreadis et al., 2007) found no association between ABCG2 mRNA levels with outcome in a series of 130 DLBCL patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Successful treatment of diffuse large B-cell lymphoma (DLBCL) is frequently hindered by the development of resistance to conventional chemotherapy resulting in disease relapse and high mortality. High expression of antiapoptotic and/or drug transporter proteins induced by oncogenic signaling pathways has been implicated in the development of chemoresistance in cancer. Previously, our studies showed that high expression of adenosine triphosphate-binding cassette drug transporter ABCG2 in DLBCL correlated inversely with disease- and failure-free survival. In this study, we have implicated activated hedgehog (Hh) signaling pathway as a key factor behind high ABCG2 expression in DLBCL through direct upregulation of ABCG2 gene transcription. We have identified a single binding site for GLI transcription factors in the ABCG2 promoter and established its functionality using luciferase reporter, site-directed mutagenesis and chromatin-immunoprecipitation assays. Furthermore, in DLBCL tumor samples, significantly high ABCG2 and GLI1 levels were found in DLBCL tumors with lymph node involvement in comparison with DLBCL tumor cells collected from pleural and/or peritoneal effusions. This suggests a role for the stromal microenvironment in maintaining high levels of ABCG2 and GLI1. Accordingly, in vitro co-culture of DLBCL cells with HS-5 stromal cells increased ABCG2 mRNA and protein levels by paracrine activation of Hh signaling. In addition to ABCG2, co-culture of DLBCL cells with HS-5 cells also resulted in increase expression of the antiapoptotic proteins BCL2, BCL-xL and BCL2A1 and in induced chemotolerance to doxorubicin and methotrexate, drugs routinely used for the treatment of DLBCL. Similarly, activation of Hh signaling in DLBCL cell lines with recombinant Shh N-terminal peptide resulted in increased expression of BCL2 and ABCG2 associated with increased chemotolerance. Finally, functional inhibition of ABCG2 drug efflux activity with fumitremorgin C or inhibition of Hh signaling with cyclopamine-KAAD abrogated the stroma-induced chemotolerance suggesting that targeting ABCG2 and Hh signaling may have therapeutic value in overcoming chemoresistance in DLBCL.
    Oncogene 05/2011; 30(49):4874-86. DOI:10.1038/onc.2011.195 · 8.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To identify novel polymorphisms in the solute carrier SLC22A16 gene and determine their influence on the pharmacokinetics of doxorubicin and doxorubicinol in Asian breast cancer patients. SLC22A16 coding regions were screened in a total of 400 healthy subjects belonging to three distinct Asian ethnic groups (Chinese [n = 100], Malays [n = 100] and Indians [n = 100]) and in the Caucasian population (n = 100). Pharmacokinetic parameters of doxorubicin and doxorubicinol were estimated in Asian breast cancer patients undergoing adjuvant chemotherapy to investigate genotype-phenotype correlations. Four novel polymorphisms (c.146A>G [exon 2], c.312T>C, c.755T>C [exon 4] and c.1226T>C [exon 5]) were identified. The genotypic frequency of the homozygous c.146GG polymorphism was approximately twofold higher in the healthy Chinese (13%) & Malay (18%) populations compared with the Indian (7%) and Caucasian (9%) populations. The genotypic frequency of the c.1226T>C polymorphism was observed to be significantly higher among the Caucasian (11%) and Indian (8%) study subjects compared with the Chinese (1%) and Malay (1%) ethnic groups (p < 0.005 in each case). Breast cancer patients harboring the 146GG genotype showed a trend towards higher exposure levels to doxorubicin (AUC(0 negative infinity)/dose/body surface area [BSA] [hm(-5)]: 21.6; range: 18.8-27.7) compared with patients with either the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 17.4; range: 8.2-26.3, p = 0.066) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 15.4; range: 6.2-38.0, p = 0.055). The exposure levels of doxorubicinol were also higher in patients harboring the variant 146GG genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 13.3; range: 8.8-21.7) when compared with patients harboring the reference genotype (AUC(0 negative infinity)/dose/BSA[hm(-5)]): 9.8; range: 6.1-24.3, p = 0.137) or heterozygotes (AUC(0 negative infinity)/dose/BSA[hm(-5)]: 8.98; range: 3.7-20.6, p = 0.047). Among the four novel SLC22A16 polymorphisms identified, the c.146A>G and c.1226T>C polymorphisms exhibited interethnic variations in allele and genotype frequencies. This exploratory study suggests that the c.146A>G variation could contribute to the variations in the pharmacokinetics of doxorubicin and doxorubicinol in Asian cancer patients. Further in vitro studies are required to determine the functional impact of these novel polymorphisms on doxorubicin pharmacokinetics in cancer patients.
    Pharmacogenomics 06/2007; 8(6):567-75. DOI:10.2217/14622416.8.6.567 · 3.43 Impact Factor
Show more